Cargando…

Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome

Visual evoked potentials (VEP) are changes in potentials that arise in the central nervous system. In the interpretation of the VEP test results, it is assumed that the elongation of the latency time is caused by the demyelination of the nerve fibers, and the axon damage is responsible for the decre...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziadkowiak, Edyta, Sebastian, Agata, Wieczorek, Malgorzata, Pokryszko-Dragan, Anna, Madej, Marta, Waliszewska-Prosół, Marta, Budrewicz, Sławomir, Wiland, Piotr, Ejma, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467284/
https://www.ncbi.nlm.nih.gov/pubmed/34575305
http://dx.doi.org/10.3390/jcm10184196
_version_ 1784573358020493312
author Dziadkowiak, Edyta
Sebastian, Agata
Wieczorek, Malgorzata
Pokryszko-Dragan, Anna
Madej, Marta
Waliszewska-Prosół, Marta
Budrewicz, Sławomir
Wiland, Piotr
Ejma, Maria
author_facet Dziadkowiak, Edyta
Sebastian, Agata
Wieczorek, Malgorzata
Pokryszko-Dragan, Anna
Madej, Marta
Waliszewska-Prosół, Marta
Budrewicz, Sławomir
Wiland, Piotr
Ejma, Maria
author_sort Dziadkowiak, Edyta
collection PubMed
description Visual evoked potentials (VEP) are changes in potentials that arise in the central nervous system. In the interpretation of the VEP test results, it is assumed that the elongation of the latency time is caused by the demyelination of the nerve fibers, and the axon damage is responsible for the decrease in the amplitude. The observed VEP deviations are not specific for specific diseases, but indicate disturbances in visual conductivity. VEP may play a diagnostic role in the early detection of visual involvement. The aim of the study was the functioning of visual pathway assessment on the basis of visual evoked potentials (VEP) examination, in patients with primary Sjögren’s Syndrome (pSS), without focal symptoms of central nervous system disorder. The effect of disease activity, as assessed by clinical parameters and antibody levels (anti-Ro52, SSA, and SSB), on the central nervous system was also evaluated. Thirty-two consecutive patient with pSS (31 females, 1 male) were included in the study. VEP was performed at baseline, and after 6 (T6) years. Their results were compared longitudinally between the baseline and T6, depending on the duration of the disease and treatment. The immunological activity of pSS was also analyzed. The group of patients showed a significant prolongation of the P100 implicit time (105.5 ± 5.1 vs. 100.6 ± 3.9; p = 0.000) and a significant higher the P100-N145 amplitude (12.3 ± 4.1 vs. 9.4 ± 3.0; p = 0.000). Abnormalities in electrophysiological parameters of VEP at baseline correlated with presentation of anti-Ro52 antibodies and aching joints. At baseline, the P100 implicit time was shorter for the patients with pSS than for those at T6 (105.50 ± 5.1 vs. 109.37 ± 5.67; p = 0.002). pSS patients without CNS involvement presented with dysfunction of visual pathway, as revealed by VEP abnormalities. Relationships were found between VEP parameters and with present of anti-Ro52 antibodies and aching joints. VEP may be a useful method for assessment and monitoring of subclinical visual deficit in the course of pSS.
format Online
Article
Text
id pubmed-8467284
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84672842021-09-27 Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome Dziadkowiak, Edyta Sebastian, Agata Wieczorek, Malgorzata Pokryszko-Dragan, Anna Madej, Marta Waliszewska-Prosół, Marta Budrewicz, Sławomir Wiland, Piotr Ejma, Maria J Clin Med Article Visual evoked potentials (VEP) are changes in potentials that arise in the central nervous system. In the interpretation of the VEP test results, it is assumed that the elongation of the latency time is caused by the demyelination of the nerve fibers, and the axon damage is responsible for the decrease in the amplitude. The observed VEP deviations are not specific for specific diseases, but indicate disturbances in visual conductivity. VEP may play a diagnostic role in the early detection of visual involvement. The aim of the study was the functioning of visual pathway assessment on the basis of visual evoked potentials (VEP) examination, in patients with primary Sjögren’s Syndrome (pSS), without focal symptoms of central nervous system disorder. The effect of disease activity, as assessed by clinical parameters and antibody levels (anti-Ro52, SSA, and SSB), on the central nervous system was also evaluated. Thirty-two consecutive patient with pSS (31 females, 1 male) were included in the study. VEP was performed at baseline, and after 6 (T6) years. Their results were compared longitudinally between the baseline and T6, depending on the duration of the disease and treatment. The immunological activity of pSS was also analyzed. The group of patients showed a significant prolongation of the P100 implicit time (105.5 ± 5.1 vs. 100.6 ± 3.9; p = 0.000) and a significant higher the P100-N145 amplitude (12.3 ± 4.1 vs. 9.4 ± 3.0; p = 0.000). Abnormalities in electrophysiological parameters of VEP at baseline correlated with presentation of anti-Ro52 antibodies and aching joints. At baseline, the P100 implicit time was shorter for the patients with pSS than for those at T6 (105.50 ± 5.1 vs. 109.37 ± 5.67; p = 0.002). pSS patients without CNS involvement presented with dysfunction of visual pathway, as revealed by VEP abnormalities. Relationships were found between VEP parameters and with present of anti-Ro52 antibodies and aching joints. VEP may be a useful method for assessment and monitoring of subclinical visual deficit in the course of pSS. MDPI 2021-09-16 /pmc/articles/PMC8467284/ /pubmed/34575305 http://dx.doi.org/10.3390/jcm10184196 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dziadkowiak, Edyta
Sebastian, Agata
Wieczorek, Malgorzata
Pokryszko-Dragan, Anna
Madej, Marta
Waliszewska-Prosół, Marta
Budrewicz, Sławomir
Wiland, Piotr
Ejma, Maria
Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome
title Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome
title_full Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome
title_fullStr Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome
title_full_unstemmed Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome
title_short Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome
title_sort visual evoked potentials as potential biomarkers of visual function in patients with primary sjögren’s syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467284/
https://www.ncbi.nlm.nih.gov/pubmed/34575305
http://dx.doi.org/10.3390/jcm10184196
work_keys_str_mv AT dziadkowiakedyta visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome
AT sebastianagata visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome
AT wieczorekmalgorzata visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome
AT pokryszkodragananna visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome
AT madejmarta visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome
AT waliszewskaprosołmarta visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome
AT budrewiczsławomir visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome
AT wilandpiotr visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome
AT ejmamaria visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome